Marktlink → Sectors → Science & Health → Medtech

  • Updated February 27, 2026

Regulatory compliance and innovation create buyer urgency

Medtech M&A is driven by two forces: innovation premium and regulatory moat. AI-enabled devices and minimally invasive surgical instruments command exceptional multiples. MDR/IVDR compliance creates barriers to entry that buyers pay significant premiums for. Contract manufacturers with certified cleanroom capacity are scarce and sought-after. Commodity devices without IP face a competitive market.

Jeroen van den Berg

Sector Lead Science & Health • 14 years • 90+ transactions

“Medtech is where regulatory compliance becomes a competitive moat. MDR/IVDR certification costs have increased 20-30% — and that is driving consolidation among SMEs who cannot carry the compliance burden alone. For buyers, a CE-marked, MDR-compliant device portfolio is worth significantly more than the products themselves. The regulatory investment you have already made is your hidden asset.”

Sector at a Glance

  • Updated March 2, 2026
VALUATION RANGE

0.0x – 0.0x

↑ +0.4x vs 2024

EBITDA Multiple
Deals in 2025

0

Active Buyers

0+

Enter your figures → see your position instantly

Valuation Development

Medtech valuations corrected in 2023 on financing costs, then recovered strongly driven by AI devices and MDR compliance premiums.

5-Year Multiple Range

2021 PEAK

0.0x avg

COVID-driven diagnostics premium

2023 DIP

0.0x avg

Rate correction, MDR cost pressure

2025 NOW

0.0x avg

AI devices + MDR compliance premium

Subsegment Analysis

Innovative Medical Devices

[XX] deals in 2025

Multiple Range

0.0x – 0x

+0.5x
Buyer Mix
PE 25% • Strategic 65%
Key Valuation Driver
Clinical differentiation, CE/FDA clearance, and IP portfolio strength
Am I in this segment? →

Diagnostics & Imaging

[XX] deals in 2025

Multiple Range

0x – 0x

+0.4x
Buyer Mix
PE 30% • Strategic 55%
Key Valuation Driver
AI-enabled diagnostics, installed base, and reagent/consumable recurring revenue
Am I in this segment? →

Device Contract Manufacturing

[XX] deals in 2025

Multiple Range

0x – 0.0x

+0.3x
Buyer Mix
PE 40% • Strategic 45%
Key Valuation Driver
GMP/ISO 13485 compliance, cleanroom capacity, and customer diversification
Am I in this segment? →

Commodity Devices & Consumables

[XX] deals in 2025

Multiple Range

0.0x  – 0.0x

+0.1x
Buyer Mix
PE 20% • Strategic 65%
Key Valuation Driver
Distribution scale, MDR compliance status, and margin through automation
Am I in this segment? →

Buyer Landscape 2025

Overall Buyer Type Distribution

  • What drives premium valuations

CE-marked / MDR-IVDR compliant portfolio

+0.0x to +0.0x

AI/ML-enabled device with FDA/CE clearance

+0.0x to +0.0x

Recurring revenue (reagents, consumables, service)

+0.0x to +0.0x

Clinical evidence base (RCT, real-world data)

+0.0x to +0.0x

ISO 13485 / cleanroom manufacturing capacity

+0.0x to +0.0x

Which of these buyers match your firm?

BuyersChecker analyzes your profile against our active buyer database.

Recent Transactions

Anonymized Marktlink cases showing the innovation and compliance premium in medtech M&A.

AI Premium

Diagnostics

Developer of AI-enabled point-of-care diagnostic device for cardiovascular screening, CE-marked with clinical validation data from 3 European multicenter trials

REVENUE

€0.0M

EBITDA

€0.0M

MULTIPLE

0.0x

DURATION

0 months

AI-enabled diagnostics
CE-marked
3 multicenter trials

Key Insight

The AI component with clinical validation from 3 multicenter trials was the primary value driver. The global strategic buyer was acquiring both the technology and the clinical evidence base, which would have taken 3-5 years to replicate. Without AI capability, a comparable diagnostic device would trade at 5-6x.

IP & Regulatory Moat

Innovative Devices

Specialist manufacturer of minimally invasive surgical instruments for orthopedics with 15 patents, CE and FDA clearance, and OEM contracts with 3 major surgical groups

REVENUE

€0.0M

EBITDA

€0.0M

MULTIPLE

0.0x

DURATION

0 months

15 patents
CE + FDA cleared
40% disposable recurring

Key Insight

The 15-patent portfolio and dual CE/FDA clearance created a regulatory moat that buyers valued independently of current revenue. The disposable component model provided recurring revenue that improved predictability and margin quality.

Compliance Premium

Contract Manufacturing

ISO 13485-certified contract manufacturer with cleanroom production for Class IIa/IIb devices, serving 25+ medtech OEMs across DACH and Benelux

REVENUE

€0.0M

EBITDA

€0.0M

MULTIPLE

0.0x

DURATION

0 months

ISO 13485 cleanroom
25+ OEM customers
55% multi-year contracts

Key Insight

Certified cleanroom capacity for Class IIa/IIb devices is scarce in Europe. The PE buyer valued the ISO 13485 compliance and 25+ customer base as a platform for further consolidation. MDR transition has increased demand for compliant contract manufacturers.

Distribution Value

Commodity Devices

Distributor and repackager of commodity wound care products for hospitals and care institutions, limited own IP but strong distribution network in Benelux

REVENUE

€0.0M

EBITDA

-€0.0M

MULTIPLE

0.0x

DURATION

0 months

Distribution network
Limited own IP
60% framework contracts

Key Insight

Without proprietary devices or IP, the valuation was driven by the distribution network and framework contracts rather than technology. MDR compliance for simple devices is manageable, but does not create the same premium as for innovative devices.

Recognize yourself in these cases? Compare your situation.

Market Trends 2025

MDR/IVDR compliance as acquisition catalyst

MDR/IVDR full enforcement has increased certification costs by 20-30%, driving consolidation among SMEs. CE-mark renewal bottlenecks create acquisition opportunities for compliant mid-caps with validated pipelines.

Source: EY MedTech Pulse, MedTech Europe

+0–0%

certification cost increase

AI-enabled devices command premium valuations

The FDA has cleared over 1,000 AI/ML-enabled medical devices. AI diagnostics, surgical robotics, and clinical decision support command the highest premiums, with validated solutions achieving 2-3x premium over conventional devices.

Source: FDA, Nelson Advisors Jan 2026

0+

FDA-cleared AI/ML devices by mid-2025

Cross-border filings surge in Europe

Cross-border M&A filings in the Netherlands, Germany, and Ireland increased 25%+ YoY. Global medtech groups and PE firms are actively acquiring European device companies for regulatory access and innovation.

Source: EY MedTech, European Commission

+0%

YoY cross-border filings NL, DE, IE

Cardiovascular and neuro lead M&A

Cardiovascular devices dominate medtech M&A value, with J&J, Stryker, Boston Scientific, and Edwards Lifesciences driving mega-deals. Innovation in minimally invasive procedures, structural heart, and neuromodulation commands the highest multiples.

Source: Life Science Intelligence, EY

$0.0B

J&J Shockwave deal (largest 2024)

What This Means for You

Interactive tools that give you immediate insights—or full reports in your personal portal.

30 sec

Marktlink Multiple

Your estimated valuation

Direct: Indicative multiple

Portal: Detailed range + comparable deals
+ factors breakdown

Start tool

30 sec

BuyersChecker

How many buyers match you

Direct: Number of matches

Portal: Buyer profiles + alerts when
new buyers match

Start tool

30 sec

Benchmark Tool

Your performance vs sector

Direct: Position indication

Portal: Full benchmark report
+ quarterly updates

Start tool

30 sec

Buyer Appeal Scan

Which buyers want you

Direct: Top buyer type

Portal: All buyer types ranked + appeal factors
+ matching profiles

Start tool

1 min

Timing Scan

Market timing analysis

Direct: Timing score

Portal: Detailed timing report
+ market alerts

Start tool

2 min

Sale Readiness Test

How prepared are you

Direct: Readiness score

Portal: Full assessment
+ personalized action plan

Start tool

Industry Report 2025

Everything on this page, plus: 12 additional deal cases, detailed subsegment analysis, and 2026 outlook.

Follow This Sector

Receive updates when valuations change, new buyers emerge, or relevant deals close.

  • Valuation changes
  • Deal announcements
  • New buyer profiles
  • Quarterly updates